PIRS News and Press, Pieris Pharmaceuticals Inc. From 03/13/20

IDEAYA Biosciences (NASDAQ: IDYA ) initiated with Buy rating and $12 (192% upside) price target at Roth Capital. More news on: IDEAYA Biosciences, Inc., Menlo Therapeutics Inc., Amarin Corporation plc, Healthcare stocks news, Stocks on the move, , Read more ...

Pieris Pharmaceuticals, Inc. (PIRS) Q4 2019 Earnings Conference Call March 12, 2020, 08:00 ET Company Participants Thomas Bures - Principal Financial & Accounting Officer & Treasurer Stephen Yoder - CEO, President & Director Shane Olwill - SVP & Head, Translationa...

Pieris Pharmaceuticals (NASDAQ: PIRS ): FY GAAP EPS of -$0.56 beats by $0.20 . Revenue of $46.28M (+59.0% Y/Y) beats by $17.18M . Press Release More news on: Pieris Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, MARCH 12, 2020 AT 8:00 AM EDT BOSTON, MA / ACCESSWIRE / March 12, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin &#...

BOSTON, MA / ACCESSWIRE / February 25, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS ), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today an...

Gainers: Armata Pharmaceuticals (NYSEMKT: ARMP )  +104% . More news on: Armata Pharmaceuticals, Inc., NantHealth, Inc., Delphi Technologies PLC, Stocks on the move, , Read more ...

These 4 Penny Stocks On Robinhood Are Anticipating Biotechnology Results This Week The idea of buying penny stocks tends to hit certain nerves with certain people. On one hand, you have your open-minded traders who are all about making money. Penny stocks , blue-chip stocks , options, etc....

BOSTON, MA / ACCESSWIRE / November 15, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS ) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other indications, today ...

Pieris Pharmaceuticals, Inc. (PIRS) Q3 2019 Results Earnings Conference Call November 11, 2019, 08:00 AM ET Company Participants Thomas Bures - Principal Financial & Accounting Officer and Treasurer 2 Stephen Yoder - CEO, President Ingmar Bruns - VP, Clinical Development Sh...

Pieris Pharmaceuticals ( PIRS ) Q3 results : Revenues: $15.1M (+81.9%). More news on: Pieris Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...